CORRECTION OF TINNITUS AND NEUROPSYCHOLOGICAL STATUS OF PATIENTS WITH CEREBRAL ATHEROSCLEROSIS AND ESSENTIAL HYPERTENSION USING CITICOLINE AS PART OF COMPREHENSIVE THERAPY

Objective: to analyze the effect of neuroprotective therapy with citicoline in combination with hypotensive and  hypolipidemic therapy on the correction of tinnitus and neuropsychological status in patients with atherosclerosis of the brachiocephalic and cerebral arteries and essential hypertension.

Materials and methods. We examined 86 patients aged between 60 and 68 years with essential hypertension and atherosclerosis of the brachiocephalic and cerebral arteries. All patients were diagnosed with decompensated tinnitus that affected their quality of life. The Multidimensional Fatigue Inventory (MFI) was used to assess the severity of asthenic syndrome. The cognitive status was evaluated using the Schulte tables, word pair memory tests, and phrase pair memory tests. Study participants were divided into two groups. Patients in Group 1 (n = 43) received nootropic therapy with citicoline at a dose of 1000 mg/day for 3 months in addition to standard hypotensive, hypolipidemic, and antiplatelet therapies. We found that citicoline as a part of comprehensive therapy  facilitated regression of actual and moderate tinnitus in patients with atherosclerosis of the brachiocephalic and cerebral arteries and essential hypertension. This optimized the neurovegetative status of patients and improved their cognitive functions.

1. Kolpakova E.V., ZHade S.A., Kurinnaya E.A. i dr. SHum v ushah: diagnosticheskie paralleli // Innovacionnaya medicina Kubani. – 2018. – № 4 (12) . – S. 44–52.

2. McCormack A, Edmondson-Jones M, Somerset S, Hall D. A systematic review of the reporting of tinnitus prevalence and severity // Hear Res. – 2016. – № 337. – Р. 70–79.

3. Scherer RW. Effect of Tinnitus Retraining Therapy vs Standard of Care on Tinnitus-Related Quality of LifeA Randomized Clinical Trial // JAMA Otolaryngol Head Neck Surg. – 2019. – № 145 (7). – Р. 597–608.

4. Gunenkov A.V., Kosyakov S.YA. Sub"ektivnyj ushnoj shum. Sovremennye predstaleniya o lechenii // Vestnik otolaringologii. – 2014. – № 3. – S. 72–75.

5. Kolesnikov V.N., Anohin E.A., Lapin M.A. Sub"ektivnyj ushnoj shum // Glavnyj vrach. – 2017. – № 2. – S. 22–24.

6. Chari DA, Limb CJ. Tinnitus // Med Clin N Am. – 2018. – № 102 (6). – Р. 1081–1093.

7. Antipenko E.A., Erohina M.N., Kadyko A.S. Vozmozhnosti kompleksnoj nejrometabolicheskoj terapii u komorbidnogo pacienta s hronicheskoj ishemiej golovnogo mozga // Nervnye bolezni. – 2019. – № 4. – S. 16–19.

8. Vorob'eva O.V. Vozmozhnosti nootropnoj terapii pri cerebral'noj mikroangiopatii // Nervnye bolezni. – 2019. – № 1. – S. 47–52.

9. Solov'eva E.YU., Karneev A.N., CHekanov A.V. i dr. Issledovanie membranoprotektivnogo potenciala kombinacii preparatov 2-etil-6-metil-3-oksipiridina sukcinata i citikolina // ZHurnal nevrolo-gii i psihiatrii im. S.S. Korsakova. – 2018. – №118 (1). – S. 18–22.

10. Roohi-Azizi M, Arabzadeh S, Amidfar M, Salimi S, Zarindast MR, Talaei A, Akhondzadeh S. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial // Clin Neuropharmacol. – 2017. – № 40 (1). – Р. 1–5.

11. Maksimova M.YU., SHalimanova E.V. Obzor simpoziuma «Arterial'naya gipertoniya i cerebrovaskulyarnaya patologiya» na III Nacional'nom kongresse «Kardionevrologiya» // Nervnye bolezni. – 2019. – № 1. – S. 40–46.

12. Zueva I.B., Krivonosov D.S., Buch A.V. i dr. Vozmozhnosti terapii kognitivnyh narushenij u pacientov s metabolicheskim sindromom // ZHurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2018. – № 118 (5). – S. 18–22.

13. Mashin V.V., Belova L.A., Bahtogarimov I.R., Bergel'son T.M., SHarafutdinova R.R. Mnogocentrovaya nablyudatel'naya programma po ocenke effektivnosti preparata rekognan (citikolin) v korrekcii kognitivnyh narushenij u pacientov s hronicheskoj cerebrovaskulyarnoj patologiej // ZHurnal nevro-logii i psihiatrii im. S.S. Korsakova. – 2017. – № 117 (8). – S. 39–43.